{"brief_title": "An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)", "brief_summary": "A study to determine the safety, tolerability, and anti-tumor effectiveness of an oral investigational drug in the treatment of relapsed diffuse large B-cell lymphoma.", "condition": ["B-cell Lymphoma"], "intervention_type": ["Drug"], "intervention_name": ["MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months"], "criteria": "Inclusion Criteria: - Patient must be 18 years or older with relapsed Diffuse Large B-cell Lymphoma (DLBCL). - Stable disease or better for at least 3 months on most recent treatment - Have not received any chemotherapy, radiation therapy, major surgery, or any other investigational therapy for at least 4 weeks prior to entry in this study - Adequate blood testing, liver, and kidney function as required by the study. - Eligible subjects will allow tissue samples to be examined and stored. Exclusion Criteria: - Patient has been treated with other investigational agents with a similar anti-tumor mechanism. - Patient should not have failed more than 3 prior treatment regimens.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Relapsed Diffuse Large B-cell Lymphoma", "mesh_term": ["Lymphoma", "Lymphoma, B-Cell", "Lymphoma, Large B-Cell, Diffuse", "Vorinostat"], "id": "NCT00097929"}